Curated News
By: NewsRamp Editorial Staff
October 27, 2025
Aditxt Launches Clinical Study for Non-Invasive Endometriosis Test
TLDR
- Aditxt's subsidiary Pearsanta offers investors early access to a novel blood test that could disrupt the $10B endometriosis market with non-invasive diagnostics.
- Pearsanta's clinical study compares the Mitomic Endometriosis Test against laparoscopic diagnosis across 1,000 participants to validate its accuracy through systematic data collection.
- This non-invasive blood test enables earlier endometriosis detection, reducing surgical risks and improving women's health outcomes through accessible diagnostic innovation.
- Aditxt's blood test detects endometriosis markers years before symptoms appear, revolutionizing women's healthcare with cutting-edge molecular diagnostics.
Impact - Why it Matters
This development represents a potential breakthrough in women's healthcare that could fundamentally change how endometriosis is diagnosed and managed. Endometriosis affects approximately 10% of women worldwide, with many suffering for years without proper diagnosis due to the invasive nature of current diagnostic methods. The current gold standard requires laparoscopic surgery, which carries risks, costs, and recovery time that often delay diagnosis and treatment. A reliable blood-based test could enable earlier detection, reduce diagnostic delays from the current average of 7-10 years, and allow for timely intervention that could prevent disease progression and preserve fertility. For the millions of women affected by endometriosis, this innovation could mean faster diagnosis, reduced surgical procedures, and improved quality of life through earlier treatment options.
Summary
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, has reached a significant milestone through its subsidiary Pearsanta Inc., which has initiated enrollment in a groundbreaking clinical study evaluating the Mitomic® Endometriosis Test (MET™). This novel blood-based diagnostic aims to provide early detection of endometriosis, comparing its performance against laparoscopic diagnosis—the current gold standard—across up to 1,000 participants referred for surgery. The first enrollment site, Dedicated to Women OB/GYN in Dover, Delaware, has already begun recruiting participants, marking a crucial step toward validating a non-invasive alternative that could revolutionize how endometriosis is diagnosed. Pearsanta President Chris Mitton emphasized that this milestone supports the validation of a diagnostic tool that could enable earlier and more accurate detection, potentially transforming patient care for millions of women worldwide.
Aditxt operates as a unique social innovation platform that accelerates promising health innovations through its ecosystem of research institutions, industry partners, and shareholders. The company's mission to "Make Promising Innovations Possible Together" drives its strategy of democratizing innovation and ensuring every stakeholder's voice is heard and valued. Currently, Aditxt operates four key programs focused on autoimmunity, cancer and early disease detection, infectious diseases, and women's health, with the endometriosis test representing a significant advancement in the latter category. The company's innovative platform serves as the cornerstone of its strategy, where multiple disciplines collaborate to drive disruptive growth and address significant societal health challenges, positioning Aditxt at the forefront of medical innovation.
This announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN that provides advanced wire-grade press release syndication for private and public companies. InvestorWire offers comprehensive distribution services including article and editorial syndication to over 5,000 outlets, enhanced press release enhancement for maximum impact, social media distribution to millions of followers, and tailored corporate communications solutions. The platform's broad reach and seasoned team of journalists and writers help companies like Aditxt effectively reach investors, influencers, consumers, and the general public, ensuring important medical breakthroughs receive the attention they deserve while cutting through today's information overload.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Aditxt Launches Clinical Study for Non-Invasive Endometriosis Test
